Research programme: tetrahydrofolate dehydrogenase inhibitors - Promiliad Biopharma/ Spero Therapeutics

Drug Profile

Research programme: tetrahydrofolate dehydrogenase inhibitors - Promiliad Biopharma/ Spero Therapeutics

Alternative Names: Dihydrofolate reductase inhibitors -Promiliad Biopharma/ Spero Therapeutics

Latest Information Update: 08 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Connecticut
  • Developer Promiliad Biopharma; Spero Therapeutics
  • Class Anti-infectives; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Gram-negative infections; Gram-positive infections; Urinary tract infections

Most Recent Events

  • 08 Mar 2016 9192972 - crosschecked, no update
  • 16 Jan 2016 Early research in Gram-positive infections in USA (PO)
  • 07 Jan 2016 Spero Therapeutics in-licenses Dihydrofolate reductase inhibitor programme from Promiliad Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top